

Denis L Jardim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9413705/publications.pdf>

Version: 2024-02-01

22
papers

349
citations

1162367

8
h-index

839053

18
g-index

24
all docs

24
docs citations

24
times ranked

656
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2022, 40, 2632-2632.	0.8	0
2	Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions. Oncologist, 2021, 26, e78-e89.	1.9	18
3	Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective. Journal of Medical Economics, 2021, 24, 291-298.	1.0	4
4	Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics. Oncologist, 2021, 26, e715-e718.	1.9	5
5	Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420). JCO Global Oncology, 2021, 7, 649-658.	0.8	19
6	Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC). JCO Global Oncology, 2021, 7, 559-571.	0.8	10
7	Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries. JCO Global Oncology, 2021, 7, 545-549.	0.8	3
8	Cardiovascular toxicity incidence following immune checkpoint inhibitors in randomized clinical trials: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2021, 39, 2636-2636.	0.8	0
9	Identification of the <i>TP53</i> p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome. JCO Global Oncology, 2021, 7, 1141-1150.	0.8	7
10	Impact of the biomarker enrichment strategy in drug development. Expert Review of Molecular Diagnostics, 2020, 20, 611-618.	1.5	5
11	Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG). Journal of Cancer Research and Clinical Oncology, 2020, 146, 1829-1845.	1.2	3
12	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. Current Oncology Reports, 2020, 22, 70.	1.8	11
13	Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. OncoImmunology, 2020, 9, 1710052.	2.1	17
14	SARS-CoV-2 testing for asymptomatic adult cancer patients before initiating systemic treatments: a systematic review. Ecancermedicalscience, 2020, 14, 1100.	0.6	5
15	Oncology Clinical Trials During the COVID-19 Pandemic. Oncology, 2020, 34, 265-269.	0.4	7
16	Renal cell cancer treatment: an expert panel recommendation from the Latin American cooperative group-genitourinary and the Latin American renal cancer group: focus on surgery. Therapeutic Advances in Urology, 2019, 11, 175628721987232.	0.9	3
17	Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. Cancer, 2019, 125, 1185-1199.	2.0	36
18	Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).. Journal of Clinical Oncology, 2019, 37, 4579-4579.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Response. Journal of the National Cancer Institute, 2016, 108, djw001.	3.0	0
20	Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. Journal of the National Cancer Institute, 2015, 107, djv253.	3.0	139
21	Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs. Clinical Cancer Research, 2014, 20, 281-288.	3.2	46
22	Expression of Sara2 Human Gene in Erythroid Progenitors. BMB Reports, 2005, 38, 328-333.	1.1	6